HIV/AIDS is the #1 cause of death among women ages 15-44 worldwide, and in sub-Saharan Africa, nearly two-thirds (64%) of all new infections in young people ages 15-24 are among young women. Women need practical new tools they can use to protect themselves against HIV.

PARTNERSHIPS WERE CRITICAL TO THE RING’S DEVELOPMENT:

In 2016, a monthly vaginal ring containing the ARV dapivirine was shown to safely help reduce a woman’s risk of HIV infection. Developed by the nonprofit International Partnership for Microbicides (IPM), the ring next moves to open-label studies and regulatory review.

A Shared Passion

Partnerships were critical to the development of the dapivirine ring, which offers new hope for expanding women’s HIV prevention options. Only through continued partnership can we realize the ring’s potential and get it to the women who could benefit from it.

THE WAY FORWARD

The dapivirine ring offers new hope for expanding women’s HIV prevention options. Only through continued partnership can we realize the ring’s potential and get it to the women who could benefit from it.